Chelsea’s high‑profile winger Mykhailo Mudryk has taken his case to the Court of Arbitration for Sport (CAS) after the English Football Association handed him a four‑year ban for an alleged doping violation. The CAS registry shows that Mudryk lodged his appeal on 25 February, but to date neither the FA, Chelsea nor the player’s legal team have issued any public statements regarding the matter. The Ukrainian international was signed by Chelsea from Shakhtar Donetsk in January 2023 for a reported fee of £88 million, and he remains under contract for another five years. The ban stems from a positive test for the prohibited substance meldonium, a medication that is banned in sport unless a therapeutic use exemption is granted.
Mudryk maintains that the sample was contaminated while he was representing Ukraine on international duty in October 2024, and he insists he never knowingly ingested a banned product. The timeline of events began in December 2024, when the FA provisionally suspended Mudryk after the initial laboratory result indicated a breach of anti‑doping rules. In a press release issued that same month, Mudryk described the outcome as "a complete shock" and affirmed his innocence, stating that he had done nothing wrong. Chelsea quickly launched its own internal review, emphasizing that the 23‑year‑old player had repeatedly told club officials that he had never deliberately taken any prohibited substance.
Since the provisional suspension, Mudryk has been training away from Chelsea’s Cobham facilities under the guidance of his personal trainers, keeping himself in peak physical condition while the legal process unfolds. The player’s contract still binds him to the club, but the ban effectively bars him from competitive action for the duration of the sanction, should the appeal be rejected. Sky Sports’ chief correspondent Kaveh Solhekol explained the limited information available: "The only reason we know Mudryk has been banned by the Football Association is because it’s been confirmed by CAS that he has appealed against it to them.
The FA themselves have said absolutely nothing, because this is a confidential process. Chelsea have said nothing, and the player's lawyers are saying nothing either." Solhekol added context about Mudryk’s career trajectory.
The winger arrived in London as one of the most expensive signings in the club’s modern era, yet he has not featured for the first team since a 2‑0 victory over German side Heidenheim in the UEFA Conference League on 28 November 2024. That match marked his last appearance and his last goal for Chelsea, leaving a gap of nearly 18 months without competitive football. If CAS upholds the FA’s decision, Mudryk’s ban would run until the end of 2028, effectively ending his playing career at the club and severely damaging both his personal prospects and Chelsea’s long‑term plans for the player.
The potential loss is especially painful for a club that invested heavily in his talent, hoping he would become a cornerstone of their attacking line‑up. The appeal process at CAS will involve a thorough review of the testing procedures, the chain of custody for the sample, and any evidence Mudryk can present to demonstrate contamination or procedural error. Legal experts note that meldonium cases can be complex, as the substance can appear in trace amounts in certain foods or supplements, and the World Anti‑Doping Agency (WADA) has specific thresholds for what constitutes a violation. Mudryk’s legal team is expected to argue that the sample was collected during an international fixture, not while he was training or playing for Chelsea, and that the environment in which the sample was taken may have contributed to inadvertent exposure.
They may also request a re‑analysis of the original sample or the testing of a B‑sample, which could either confirm or refute the initial findings. In the meantime, Chelsea has adopted a wait‑and‑see approach, indicating that the club will respect the outcome of the arbitration and allow the process to run its course. The club’s statement, though brief, emphasized its commitment to supporting the player while also upholding the integrity of the sport. The broader football community is watching closely, as this case highlights the ongoing challenges of anti‑doping enforcement in a global sport where players travel frequently for club and country duties.
It also raises questions about the responsibilities of national associations, clubs, and players in ensuring that anti‑doping protocols are strictly adhered to. Regardless of the final ruling, Mudryk’s appeal underscores the high stakes involved when a player’s career is jeopardized by a doping allegation. The next few months will be crucial in determining whether he can return to the Premier League stage or whether his time at Chelsea will be remembered more for the controversy than for his on‑field contributions.